This edition presents data from the preclinical study conducted by Cryopraxis in partnership with UFRJ, published in Stem Cells International (Hindawi, 2020). The study investigated the systemic safety and in vivo localization of human adipose tissue-derived mesenchymal stromal cells (ASCs) combined with hyaluronic acid (1% HA), using radioisotope tracking (99mTc) and SPECT/CT image fusion.
Hyaluronic acid (HA) is currently the most widely used filler in aesthetic medicine — but its durability is limited by degradation through native hyaluronidase, with resorption expected within 12 to 18 months. The literature had already indicated that combining ASCs with biomaterials enhances the in situ generation of differentiated cells and extracellular matrix production, resulting in longer-lasting effects than fillers alone.
However, two critical aspects remained underexplored: (1) what is the systemic safety profile of this combination? and (2) do the cells remain at the injection site or migrate to other organs? This study was designed to address precisely these questions, in accordance with ISO 10993 and regulatory agency guidance (FDA/EMA).
Machado et al. "Safety and Localization of Mesenchymal Stromal Cells Derived from Human Adipose Tissue-Associated Hyaluronic Acid: A Preclinical Study." Stem Cells International, vol. 2020, Article ID 1823427. DOI: 10.1155/2020/1823427. Cryopraxis / UFRJ / Hospital Bonsucesso.
ASCs were obtained from 20 female patients undergoing cosmetic liposuction at Hospital Bonsucesso (Rio de Janeiro). After isolation of the stromal vascular fraction (SVF) and culture to passage 3, the cells were characterized by immunophenotyping and trilineage differentiation potential (adipogenic, osteogenic, chondrogenic).
The immunophenotypic profile confirmed the MSC pattern (ISCT/Dominici criteria): CD105⁺, CD73⁺, CD90⁺ >95%; CD45⁻, CD34⁻ at passage 3. Trilineage differentiation capacity was validated with Oil Red O (adipogenic), Alizarin Red (osteogenic), and Alcian Blue (chondrogenic).
For the in vivo assays, 150 male Wistar rats were allocated to groups receiving subcutaneous injections of: saline (negative control), 1% HA, ASCs alone, ASCs + 1% HA (filler agent), and Freund's complete adjuvant (positive inflammatory control). Follow-up took place at 3, 14, 28, and 42 days after injection.
For cell tracking, ASCs were labeled with 99mTc (labeling efficiency: 85%; post-labeling viability: 95%) and injected with or without HA. Localization was assessed by SPECT/CT fusion (OsiriX software) at 3 and 24 hours after injection.
Phase-contrast photomicrographs (100×, 50 µm scale) of ASCs obtained from human lipoaspirate at passage 3 — the same cells used in this study's safety assays. The characteristic spindle-shaped morphology of MSCs is preserved after culture (a, b). Clonogenic potential was assessed using the colony-forming unit-fibroblast (CFU-F) assay (c). The exponential growth curve (d) confirms high proliferative capacity, with population doubling in approximately 24 hours — parameters included in Cryopraxis's cell quality control protocol.
Adapted figure — Machado et al., Stem Cells International, 2020. DOI: 10.1155/2020/1823427.
ASCs at passage 3: spindle-shaped morphology (a, b), CFU-F (c), and 0–72-hour growth curve (d).
Results were consistent across all parameters assessed. A summary of the critical findings follows:
| Parameter Assessed | ASC + 1% HA Result | Status |
|---|---|---|
| Observed mortality | Zero deaths across all groups | Safe |
| Body weight variation | No statistically significant difference between groups (ANOVA + Bonferroni) | Safe |
| Hematology (complete blood count) | Values within reference ranges on D14, D28, and D42 | Safe |
| Biochemistry (albumin, ALT, AST, creatinine, urea, glucose) | No changes indicative of hepatic or renal toxicity | Safe |
| Systemic hypersensitivity | Absent. Slight edema and mild erythema at the site, resolved within 72 hours | Safe |
| Cell migration to organs (SPECT/CT) | 99mTc-ASC cells retained at the injection site at 3 and 24 hours. No detectable migration | Retained |
| Tissue inflammation (H&E) | Expected mild subacute inflammation, comparable to the HA-only group | Expected |
"The filler agent (ASCs + 1% HA) did not result in systemic, biochemical, or anatomical changes
that could represent symptoms of toxicity. The cells remained at the injection site — an essential
condition for supporting local tissue repair through the secretion of paracrine factors."
— Machado et al., Stem Cells International, 2020
Hyaluronic acid acts as a three-dimensional matrix that prevents excessive ASC diffusion, allowing sustained release at the injection site. The interaction occurs partly through the CD44 receptor, present on the surface of MSCs. This mechanism is clinically relevant because keeping cells at the site is a prerequisite for the local paracrine effect: collagen synthesis by fibroblasts, dermal angiogenesis, anti-inflammatory modulation, and fibroblast protection — all mediated by factors secreted by ASCs in the local microenvironment.
The stiffness and elasticity of the microenvironment also influence ASC differentiation. A 3D matrix such as HA provides structural support that preserves the ASC phenotype and enhances their tissue repair capacity — a result consistent with data from in vitro studies cited by the authors.
Cells that migrate to other sites lose their ability to contribute locally. SPECT/CT fusion confirms that HA functions as a biological anchor for ASCs.
ASCs produce anti-inflammatory cytokines and angiogenic, neurotrophic, and antiapoptotic factors. This paracrine secretome is responsible for inducing collagen synthesis and local dermal angiogenesis.
The ASC + HA combination produces longer-lasting effects than cell-free fillers by generating new differentiated tissues in situ and promoting ECM production — not merely transient volume enhancement.
This study provides a direct scientific basis for LipAge's safety pillar. The data demonstrate that:
First, human adipose tissue-derived ASCs, when appropriately processed and characterized according to ISCT criteria, show an acceptable safety profile in robust preclinical models — including hematological, biochemical, and histological assessment over 42 days.
Second, chain of custody and processing quality control are decisive: the study used passage 3 ASCs with confirmed immunophenotyping and viability >95%. This reinforces the importance of processing at a licensed Cell Technology Center — precisely the infrastructure Cryopraxis provides as a Cell Technology Center licensed by ANVISA (Brazil's health regulatory agency) and accredited by AABB.
Third, cell retention at the injection site — confirmed by nuclear imaging — is the biological property underpinning the rationale for autologous banking: stored material, when indicated by the attending physician and used at the appropriate time, has the potential to contribute locally, rather than systemically.
This is a preclinical study (animal model) investigating the ASC + HA combination as an advanced cellular product. Within its current launch scope (LipAge Fill), LipAge operates as a service for the cryopreservation and storage of autologous adipose tissue, without any clinical claims or specific clinical use indications. Use of cryopreserved material is solely at the discretion of the attending physician, based on their clinical assessment and current ANVISA and CFM (Brazil's Federal Council of Medicine) regulations. The data from this publication are presented exclusively for the scientific education of medical professionals.
The authors themselves clearly define the scope of the data:
24-hour follow-up for cell tracking: The nuclear imaging observation period (SPECT/CT) was limited to 24 hours by the half-life of 99mTc. This demonstrates initial retention, but does not allow inferences about long-term persistence. Studies using longer-lasting markers (e.g., MRI with nanoparticles) are needed to demonstrate prolonged engraftment.
Model without disease: The experiments were conducted in rats without disease or induced lipodystrophy. Studies in pathological models would be needed to assess efficacy in clinically relevant conditions.
Scale and standardization for clinical use: The authors emphasize that randomized clinical trials with standardized protocols are still needed before broad clinical application of any cell-based product, in accordance with FDA and EMA requirements.
Available as open access on the Hindawi / Stem Cells International platform.
Contact us for LipAge technical materials and service information.